Financial reports
NT 10-K
Notice of late annual filing
18 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
29 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
10-K
2021 FY
Annual report
31 Mar 22
Current reports
8-K
Nebula Genomics secures major international B2B deal – Additional significant B2B deals in final stages
15 Mar 24
8-K
ProPhase poised to ramp up growth at Pharmaloz and Nebula Genomics in 2024
4 Jan 24
8-K
ProPhase Labs Announces Financial Results
9 Nov 23
8-K
ProPhase Labs Announces Financial Results
10 Aug 23
8-K
Navidea Biopharmaceuticals Rejects ProPhase Labs Offer To Acquire Certain Assets of Navidea
29 Jun 23
8-K
Regulation FD Disclosure
22 Jun 23
8-K
Amendments to Articles of Incorporation or Bylaws
20 Jun 23
8-K
Departure of Directors or Certain Officers
20 Jun 23
8-K
ProPhase Labs Announces Financial Results
11 May 23
8-K
Regulation FD Disclosure
25 Apr 23
Registration and prospectus
S-8
Registration of securities for employees
14 Nov 22
S-8
Registration of securities for employees
27 May 22
424B5
Prospectus supplement for primary offering
29 Dec 21
S-8
Registration of securities for employees
1 Dec 21
POS AM
Prospectus update (post-effective amendment)
18 Nov 21
S-3
Shelf registration
5 Nov 21
S-8
Registration of securities for employees
23 Aug 21
S-3
Shelf registration
21 Jun 21
S-8
Registration of securities for employees
3 Jun 21
424B5
Prospectus supplement for primary offering
20 Jan 21
Proxies
DEF 14A
Definitive proxy
27 Apr 23
DEF 14A
Definitive proxy
13 Apr 22
DEF 14A
Definitive proxy
16 Apr 21
DEF 14A
Definitive proxy
16 Apr 20
DEF 14A
Definitive proxy
19 Apr 19
DEF 14A
Definitive proxy
19 Apr 18
DEF 14A
Definitive proxy
23 Mar 18
PRE 14A
Preliminary proxy
28 Feb 18
DEF 14A
Definitive proxy
20 Apr 17
DEF 14A
Definitive proxy
3 Mar 17
Other
EFFECT
Notice of effectiveness
26 Nov 21
EFFECT
Notice of effectiveness
12 Nov 21
CORRESP
Correspondence with SEC
10 Nov 21
UPLOAD
Letter from SEC
9 Nov 21
EFFECT
Notice of effectiveness
30 Jun 21
CORRESP
Correspondence with SEC
25 Jun 21
UPLOAD
Letter from SEC
24 Jun 21
UPLOAD
Letter from SEC
22 Jun 21
CORRESP
Correspondence with SEC
11 Jun 21
UPLOAD
Letter from SEC
26 May 21
Ownership
4/A
Ted William Karkus
21 Mar 24
4
Jed Latkin
19 Mar 24
3
Jed Latkin
19 Mar 24
4
Warren Hirsch
19 Mar 24
4
LOUIS MD GLECKEL
19 Mar 24
4
Jason Michael Barr
19 Mar 24
4
Ted William Karkus
19 Mar 24
SC 13D/A
Karkus Ted William
19 Mar 24
SC 13G/A
Lantern Pharma Inc.
14 Feb 24
4/A
Warren Hirsch
22 Jun 23